WO1998043654A1 - Non-aqueous colonic purgative formulations - Google Patents
Non-aqueous colonic purgative formulations Download PDFInfo
- Publication number
- WO1998043654A1 WO1998043654A1 PCT/US1998/006224 US9806224W WO9843654A1 WO 1998043654 A1 WO1998043654 A1 WO 1998043654A1 US 9806224 W US9806224 W US 9806224W WO 9843654 A1 WO9843654 A1 WO 9843654A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnesium
- phosphate
- sodium
- purgative
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- 230000001543 purgative effect Effects 0.000 title claims abstract description 67
- 239000008141 laxative Substances 0.000 title claims abstract description 63
- 238000009472 formulation Methods 0.000 title claims abstract description 43
- 230000000112 colonic effect Effects 0.000 title abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims abstract description 24
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 19
- 210000001072 colon Anatomy 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 16
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical class [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims abstract description 15
- 229940075110 dibasic magnesium phosphate Drugs 0.000 claims abstract description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000011230 binding agent Substances 0.000 claims abstract description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 8
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims abstract description 8
- 229940095060 magnesium tartrate Drugs 0.000 claims abstract description 7
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims abstract description 7
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 claims abstract description 7
- 239000001472 potassium tartrate Substances 0.000 claims abstract description 7
- 229940111695 potassium tartrate Drugs 0.000 claims abstract description 7
- 235000011005 potassium tartrates Nutrition 0.000 claims abstract description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 claims abstract description 7
- 235000011152 sodium sulphate Nutrition 0.000 claims abstract description 7
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims abstract description 6
- 239000001433 sodium tartrate Substances 0.000 claims abstract description 6
- 229960002167 sodium tartrate Drugs 0.000 claims abstract description 6
- 235000011004 sodium tartrates Nutrition 0.000 claims abstract description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 52
- -1 Mg(OH)2 citrate salts Chemical class 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 13
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- QQFLQYOOQVLGTQ-UHFFFAOYSA-L magnesium;dihydrogen phosphate Chemical compound [Mg+2].OP(O)([O-])=O.OP(O)([O-])=O QQFLQYOOQVLGTQ-UHFFFAOYSA-L 0.000 claims description 12
- 239000010452 phosphate Substances 0.000 claims description 12
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 239000011777 magnesium Substances 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 239000006172 buffering agent Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000347 magnesium hydroxide Substances 0.000 claims description 7
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 229940035053 monobasic magnesium phosphate Drugs 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 229960002920 sorbitol Drugs 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- UOVKYUCEFPSRIJ-UHFFFAOYSA-D hexamagnesium;tetracarbonate;dihydroxide;pentahydrate Chemical compound O.O.O.O.O.[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O UOVKYUCEFPSRIJ-UHFFFAOYSA-D 0.000 claims description 4
- 229940031958 magnesium carbonate hydroxide Drugs 0.000 claims description 4
- 239000004337 magnesium citrate Substances 0.000 claims description 4
- 229960005336 magnesium citrate Drugs 0.000 claims description 4
- 235000002538 magnesium citrate Nutrition 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 3
- 241001116389 Aloe Species 0.000 claims description 3
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- 239000010369 Cascara Substances 0.000 claims description 3
- 235000006693 Cassia laevigata Nutrition 0.000 claims description 3
- 241000556215 Frangula purshiana Species 0.000 claims description 3
- 244000134552 Plantago ovata Species 0.000 claims description 3
- 235000003421 Plantago ovata Nutrition 0.000 claims description 3
- 239000009223 Psyllium Substances 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229960004977 anhydrous lactose Drugs 0.000 claims description 3
- 229960000503 bisacodyl Drugs 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- DWKPZOZZBLWFJX-UHFFFAOYSA-L calcium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate Chemical compound [Ca+2].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC DWKPZOZZBLWFJX-UHFFFAOYSA-L 0.000 claims description 3
- 229940071704 cascara sagrada Drugs 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001577 dantron Drugs 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 150000003893 lactate salts Chemical class 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 3
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 3
- 239000000626 magnesium lactate Substances 0.000 claims description 3
- 235000015229 magnesium lactate Nutrition 0.000 claims description 3
- 229960004658 magnesium lactate Drugs 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 claims description 3
- 229940074439 potassium sodium tartrate Drugs 0.000 claims description 3
- 229940070687 psyllium Drugs 0.000 claims description 3
- 229940124513 senna glycoside Drugs 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 235000011006 sodium potassium tartrate Nutrition 0.000 claims description 3
- 239000000196 tragacanth Substances 0.000 claims description 3
- 235000010487 tragacanth Nutrition 0.000 claims description 3
- 229940116362 tragacanth Drugs 0.000 claims description 3
- 241000522641 Senna Species 0.000 claims 2
- 239000013061 administrable dose form Substances 0.000 claims 2
- 229960001777 castor oil Drugs 0.000 claims 2
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 claims 2
- 229940001496 tribasic sodium phosphate Drugs 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 239000002775 capsule Substances 0.000 abstract description 8
- 239000002270 dispersing agent Substances 0.000 abstract description 5
- 235000019785 monomagnesium phosphate Nutrition 0.000 abstract description 4
- 235000019341 magnesium sulphate Nutrition 0.000 abstract description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000007832 Na2SO4 Substances 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract 1
- 235000011147 magnesium chloride Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 241000792859 Enema Species 0.000 description 12
- 239000007920 enema Substances 0.000 description 12
- 239000004135 Bone phosphate Substances 0.000 description 7
- 229940079360 enema for constipation Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 229940095399 enema Drugs 0.000 description 5
- 230000002475 laxative effect Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000002052 colonoscopy Methods 0.000 description 3
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229940096405 magnesium cation Drugs 0.000 description 3
- 229910000401 monomagnesium phosphate Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019643 salty taste Nutrition 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000735631 Senna pendula Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 125000006840 diphenylmethane group Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to colonic purgative formulations based upon inorganic salts and, more particularly, to nonaqueous purgative formulation compositions which may be administered in capsule or tablet form for preparing the colon for surgical or diagnostic procedures.
- colonoscopy radiographic examination and in preparation for patients undergoing bowel surgery
- the intestines be cleansed sufficiently, particularly with regard to the elimination of gas from the colon.
- the colon is preoperatively prepared for surgery, or for diagnostic procedures such as colonoscopies, in which case it is also necessary to remove fecal waste materials.
- Typical prior art colonic purgative procedures involved the emptying of the colon using water enemas wherein large quantities of water are introduced into the colon to induce emptying- the contents of the colon being expelled in the form of a suspension. It has, however, been recognized that the use of enemas may be injurious to the patient.
- an alternative has been to introduce enemas of a hypertonic aqueous solution typically, of various salts to substitute for the large water enema.
- the advantage of these salt formulations is that they require significantly less water volume in their administration.
- hypertonic enemas The effect of these hypertonic enemas is based on the increase of the osmotic pressure in the colon which, in turn, may have undesirable side effects, particularly, if the hypertonic solution diffuses through the wall of the colon and disturbs the fluid balance of the body. Although this is an improvement over simple water enemas, this potential side effect limits the utility of these compositions.
- enema compositions in aqueous solutions include a contact laxative agent causing peristalsis in the colon with sufficient concentration of laxation without the need for excessive amounts of water.
- Such compositions often include salt mixtures and may also contain chemical agents such as propylene glycol and non-ionic wetting agents such as polyether alcohols.
- the problems with these formulations aside from the often problematic methods of enema administration, are incomplete evacuation of the bowels, repeat administrations and the inclusion of certain chemicals which may have an irritating effect on the colonic walls. Furthermore, because it is often necessary to employ repeated washout enemas to clear the colon effectively, the potential for such chemical irritation is greatly increased.
- compositions for use as gastrointestinal washes for diagnostic purposes or for use as cathartic laxatives.
- Such preparations consist of aqueous solutions of polyethylene glycol and electrolytes suchs as sodium sulfate, sodium bicarbonate, sodium chloride and potassium chloride.
- These orally administered compositions are particularly useful in the rapid washing of the colon for diagnostic purposes.
- a powerful gastrointestinal wash is required, such preparations are generally administered in a quantity of about four liters, the composition being typically formulated according to the following: polyethylene glycol 59 g., sodium sulphate 5.68 g., sodium bicarbonate 1.69 g., sodium chloride 1.46 g., potassium chloride 0.745 g. and water to make up one liter.
- the advantages of using these preparations over other orally administered preparations are a drastic reduction in wash time (from 3-2 days to 4-5 hours) and the minimization of water and electrolyte losses.
- the advantages which these types of solutions provide are derived from two essential characteristics of the preparation, namely, its isoosmoticity with the physiological liquids, and the balance of the ion species in solution, so as to compensate the transport mechanisms which regulate gastrointestinal absorption. These characteristics result in substantial isotonicity between the preparation and the intracellular and extracellular fluids at the tissues of the digestive tubes walls.
- ingestible preparations which consist of aqueous solutions of phosphate salts.
- the aqueous phosphate salt solution produces a tremendous osmotic effect on the intra-luminal contents of the bowel and therefore, evacuation of the bowel occurs with a tremendous increase in the influx of water and electrolytes into the colon.
- This has been developed for the express purpose of decreasing the volume required in colonic purgations.
- One such preparation basically is comprised of 480 grams per liter monobasic sodium phosphate and 180 grams per liter dibasic sodium phosphate in stabilized buffered aqueous solution and is sold under the brand name Fleets Phospho-Soda tm . Patients are typically required to take two three ounce dosages of this preparation, separated by a three hour interval for a total of six ounces, which is a significant reduction compared to large volumes required by other high volume preparations.
- Yet another object of theinstant invention is to provide a formulation for colonic purgatives which avoids the addition of other components which may be broken down by intestinal flora.
- the present invention relates to colonic purgative formulations in which are contained purgative active amounts of a salt selected from the group consisting of Mg 3 (PO 4 ) 2 MgHPO 4 Mg (H 2 PO 4 ) 2 , MgSO 4 MgCl 2 Na 2 SO 4 ⁇ potassium tartrate, sodium tatrate and magnesium tartrate and mixtures, thereof, in a stable, nonaqueous tablet dosage form.
- the dosage formulation comprises dibasic magnesium phosphate (MgHPO 4 ).
- the formulation comprises an effective amount of a purgative salt, preferably, dibasic magnesium phosphate, comprising approximately 0.05 to about 2.0 grams per kilogram body weight which may be conveniently administered to the patient in a tablet or capsule form.
- the patient dosage of the purgative salt falls within the range of about 0.1 to about 1.2 grams per kilogram body weight, magnesium phosphate salts, more preferably about 0.2 to 0.7 grams per kilogram bodyweight.
- the salt is magnesium hydrogen phosphate (dibasic magnesium phosphate) or a mixture of magnesium hydrogen phosphate and magnesium dihydrogen phosphate (monobasic magnesium phosphate).
- the formulation may be a mixture of dibasic magnesium phosphate and monobasic magnesium phosphate wherein the total amount of the two salts falls within the above ranges.
- the formulations according to the present invention may further include tablet binders, dispersants and/or buffering agents. Further, in other embodiments, the formulation may include tribasic magnesiium phosphate in addition to either monobasic or dibasic magnesium phosphate, or both, within the above ranges.
- patient is used throughout the specification to describe an animal, preferably a human, to whom treatment with the compositions according to the present invention is provided.
- the term patient refers to that specific animal.
- the term “patient” will refer to human patients.
- salts according to the present invention may be found in their anhydrous form or as in hydrated crystalline form (i.e., complexed or crystallized with one or more molecules of water).
- Purgative salts for use in the present invention include, for example, Mg 3 (PO 4 ) 2 MgHPO 4 Mg(H 2 PO 4 ) 2 MgSQ, MgClj Na ⁇ O,, sodium tartrate, potassium tartrate, magnesium tartrate, or mixtures, thereof.
- Preferred salts include the magnesium phosphate salts, with a particularly preferred salt being magnesium monohydrogen phosphate (dibasic magnesium phosphate) or a mixture of magnesium monohydrogen phosphate and magnesium dihydrogen phosphate salts.
- the magnesium phosphate salts are preferred for use in the present invention because of the dual effect which is produced by both the phosphate anion and the magnesium cation.
- the magnesium phosphate salts may be utilized in the present invention in amounts which are considered "low dose", i.e. in an amount which is unexpectedly low based upon or compared to other salts, such as sodium phosphate salts which find use in anhydrous purgative formulations.
- purgative effective amount or “purgative effective dosage” is used throughout the specification to describe the amount or concentration of purgative salts used in the present invention which is effective for producing a purgative effect, i.e., the elimination or evacuation from the intestines of its contents.
- these salts have unexpectedly been found to be advantageously employed in amounts which are significantly lower than for the sodium phosphate salts.
- purgative active is used to describe salts according to the present invention which exhibit biological or pharmacological activity in the form of purgative activity.
- the term "effective amount" is that amount which is deemed effective for producing an intended result, whether the intended result or effect is a cathartic or a purgative effect.
- anhydrous is used throughout the specification describe the form in which the purgative salts according to the present invention are administered.
- Anhydrous formulations are those which essentially have excluded water from the formulations, except, in such instances where the salt is hydrated or otherwise complexed with small amounts of water.
- the present invention consists of a dry admixture of dibasic magesium phosphate or a mixture of monobasic and dibasis magnesium phosphate in an anhydrous state.
- Formulations according to the present invention may be prepared by placing one or more of the purgative salts according to the present invention, in pharmaceutical form, in a ribbon blender or other similar mung apparatus to effect complete mixing of the components. Additional constituents such as tablet binders, dispersants and/or buffering agents in the range of approximately 0.025% to 25% by weight, more preferably about 1% to 5% by weight, may also be included in the admixture.
- the formulations may be formulated in tablet or capsule form for oral delivery to a patient.
- phosphate salts are used, preferably magnesium phosphate salts and more preferably magnesium monohydrogen phosphate or mixtures of magnesium monohydrogen phosphate and magnesium dihydrogen phosphate.
- the amount of magnesium dihydrogen phosphate may be substantially reduced or eliminated in its entirety.
- dibasic phosphate or tribasic phosphate salts such as magnesium dibasic phosphate and magnesium tribasic phosphate may be used alone or in combination as the principal or exclusive form of phosphate in the formulation, while maintaining a complete purgative effect.
- Other phosphate salts according to the present invention may also be used, but these salts are less preferred.
- phosphate salts Upon ingestion, phosphate salts cause a tremendous amount of water to be drawn into the gut. This influx of water causes an increase in intraluminal pressure, which in turn exerts a mechanical stimulus causing an increase in intestinal motility.
- the purgative effect of the phosphate salts appears to be proportionately related to the increase in the anionic state of the phosphate salt and may be differentiated in their mode of action from other salt formulations which are capable of producing a limited cathartic effect.
- One such salt, magnesium sulfate for example, exerts its effect via the magnesium cation which causes hypermotility of the gut.
- magnesium phosphate salts according to the present invention exert their unexpected enhanced activity by virtue of the combined activity of the phosphate anion and magnesium cation, creating a dual effect.
- the admixture of the present invention is formed into an easily administered dosage form, such as tablets or into capsules by methods well known in the art.
- the term admixture refers to a formulation which includes at least one purgative salt, preferably a phosphate or magnesium salt, more preferably at least one magnesium phosphate salt and even more preferably magnesium hydrogen phosphate (alone or in combination with another purgative salt, preferably a magnesium phosphate salt) and at least one other component including other phosphate salts or other additives as disclosed herein.
- the salts can be compressed into a uniform mixture and can optionally include inert diluents such as a tablet binder.
- the tablet binder is a pharmaceutically acceptable binder and is one which produces no appreciable osmotic effects.
- useful binders include non-ionic detergents from the Pluronic 1 TM series, such as Pluronic F-68 (a trademark of BASF-Wyandotte Chemicals, defined as a condensate of ethylene oxide with a condensate of propylene oxide and propylene glycol), related non- ionic surfactants, and mechanical adhesives such as polyvinyl alcohol and sodium carboxymethylcellulose, among numerous others.
- Microcrystalline cellulose (MCC) may also be used to enhance the comparability of the purgative salts into the tablet or capsule form.
- MMCC Microcrystalline cellulose
- the tablet or capsules may also include inert dispersal agents which will facilitate dissolution of the tablet or capsule contents in the stomach of the patient.
- the dispersal agent is a pharmaceutically acceptable dispersant and is one which also produces no appreciable osmotic effects.
- acceptable dispersants include microcrystalline cellulose (which is also useful as a compacting agent) and anhydrous lactose.
- a preferred dispersal agent is AC-DI-SOL, a cross-linked starch.
- the preferred composition may also include a buffering agent to minimize any acid imbalance which may accompany ingestion of the purgative formulation of Applicants' invention.
- buffering agents include magnesium hydroxide, aluminum hydroxide, calcium carbonate and magnesium carbonate.
- colonic purgative formulations of the instant invention function effectively as purgatives when administered in low volume dosages, as compared to known formulations.
- 2 to 12 tablets, and preferably 4 to 10 tablets per dose, depending on tablet size and weight, with only fluids necessary to assist in swallowing the tablets, will provide complete purgation.
- the dosage may be administered in a single application but may be preferably administered in two applications separated by approximately 2 to 4 hours.
- Use of the fo ⁇ nulations of this invention in tablet form effectively removes the colonic contents without requiring injection of large quantities of water.
- Conventional purgative products historically and currently available on the market have had to employ much greater liquid volumes in order to obtain the desired result.
- a further aspect of the present invention relates to the inclusion of purgative salts disclosed herein in combination with other prior art purgatives and/or laxative compounds and/or compositions.
- any one or more of the purgative salts according to the present invention in an effective amount may be combined with and/or co- administered with an effective amount of any one or more of numerous other purgative salts and/or laxative compounds including, for example, sodium phosphate salts (mono-, di- and tribasic salts) of U.S. patent no. 5,616,346 to Craig Aronchick, related preparations of aqueous sodium phosphate salts, e.g.
- polyethylene glycol electrolytes such as sodium sulfate, sodium bicarbonate, sodium chloride and potassium chloride, among others, including Mg(OH) 2 citrate salts such as magnesium citrate, sorbitol, and magnesium carbonate hydroxide, among numerous others.
- electrolytes such as sodium sulfate, sodium bicarbonate, sodium chloride and potassium chloride, among others, including Mg(OH) 2 citrate salts such as magnesium citrate, sorbitol, and magnesium carbonate hydroxide, among numerous others.
- sodium phosphate salts may be combined with any one or more of the compounds of the present invention or of the prior art may be combined in effective amounts to produce potentially synergistic purgative activity.
- the sodium phosphate salts (mono-, di- and tribasic salts) as disclosed by Aronchick, U.S. patent no.
- the prior art phosphate salts of Aronchick may be combined with any one or more of prior art purgative or laxative compounds or compositions including, for example, aqueous sodium phosphate salts, polyethylene glycol or aqueous polyethylene glycol, electrolyte solutions such as sodium sulfate, sodium bicarbonate, sodium chloride and potassium chloride, among others, including Mg(OH) 2 citrate salts such as magnesium citrate, lactate salts such as magnesium lactate, sorbitol, magnesium carbonate hydroxide, diphenylmethanes such as phenolpththalein and bisacodyl, methyl cellulose, sodium carboxymethyl cellulose, psyllium (plantago) preparation
- a combination of the above-described compounds is administered to a patient in an amount effective to produce a purgative or cathartic/laxative effect.
- These compounds/compositions may be administered in solid or liquid (aqueous) form and are taken orally to produce the intended effect.
- One of ordinary skill may readily determine the amount and types of compounds/compositions to be used in treating a particular patient.
- the combinations of compounds/compositions as described above may be administered at the same time, or within the period of activity of a first compound/composition in order to enhance the effect of the first compound(s) or composition(s) used. In this sense combinations of compounds or compositions as described herein may be co-administered to produce an enhanced purgative effect.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU65913/98A AU6591398A (en) | 1997-03-31 | 1998-03-30 | Non-aqueous colonic purgative formulations |
JP54189598A JP3706147B2 (en) | 1997-03-31 | 1998-03-30 | Non-aqueous colonic laxative formulation |
EA199801086A EA001443B1 (en) | 1997-03-31 | 1998-03-30 | Non-aqueous colonic purgative formulations |
CA002256896A CA2256896C (en) | 1997-03-31 | 1998-03-30 | Non-aqueous colonic purgative formulations |
NZ332998A NZ332998A (en) | 1997-03-31 | 1998-03-30 | Non-aqueous colonic purgative oral formulations containing magnesium, sodium, or potassium salts of phosphates, sulphates, or tartrates |
EP98912121A EP0934071A4 (en) | 1997-03-31 | 1998-03-30 | Non-aqueous colonic purgative formulations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/829,080 US6162464A (en) | 1997-03-31 | 1997-03-31 | Non-aqueous colonic purgative formulations |
US08/829,080 | 1997-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998043654A1 true WO1998043654A1 (en) | 1998-10-08 |
Family
ID=25253475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/006224 WO1998043654A1 (en) | 1997-03-31 | 1998-03-30 | Non-aqueous colonic purgative formulations |
Country Status (10)
Country | Link |
---|---|
US (1) | US6162464A (en) |
EP (1) | EP0934071A4 (en) |
JP (3) | JP3706147B2 (en) |
KR (1) | KR20000016266A (en) |
CN (1) | CN1225588A (en) |
AU (1) | AU6591398A (en) |
CA (1) | CA2256896C (en) |
EA (1) | EA001443B1 (en) |
NZ (1) | NZ332998A (en) |
WO (1) | WO1998043654A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006017672A1 (en) * | 2006-04-12 | 2007-10-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Composition for use as a laxative |
WO2008141368A1 (en) * | 2007-05-17 | 2008-11-27 | David Lubowski | Combination laxative compositions comprising a colonic stimulant and a bulking laxative |
US7658914B2 (en) | 2002-10-25 | 2010-02-09 | Norgine Bv | Colon cleansing compositions |
US7867521B2 (en) | 2004-09-03 | 2011-01-11 | C.B. Fleet Company, Incorporated | Aspartame and citrate flavored phosphate salt laxative |
US7985429B2 (en) | 2006-03-03 | 2011-07-26 | C. B. Fleet Company, Inc. | Flavored colonic cleansing system |
US7998510B2 (en) | 2006-08-17 | 2011-08-16 | C. B. Fleet Company, Inc. | Low dose colonic cleansing system |
US8361452B2 (en) * | 2002-07-15 | 2013-01-29 | Halow George M | Bowel cleansing composition |
WO2013059881A1 (en) * | 2011-10-27 | 2013-05-02 | Borody Thomas J | Electrolyte purgatives |
US8507009B2 (en) | 2003-11-19 | 2013-08-13 | Salix Pharmaceuticals, Inc. | Colonic purgative composition with soluble binding agent |
US9468686B2 (en) | 2009-07-30 | 2016-10-18 | Norgine Bv | Solutions comprising polyethylene glycol and electrolytes |
US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
CN111024691A (en) * | 2019-12-26 | 2020-04-17 | 上海瘦斯网络科技有限公司 | Granules for absorbing animal urine and preparation method and application thereof |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162464A (en) * | 1997-03-31 | 2000-12-19 | Inkine Pharmaceutical, Inc. | Non-aqueous colonic purgative formulations |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
AUPS088702A0 (en) | 2002-03-04 | 2002-03-28 | Borody, Thomas Julius | Electrolyte purgative |
US6946149B2 (en) | 2002-04-30 | 2005-09-20 | Braintree Laboratories, Inc. | Salt solution for colon cleansing |
DE60320429D1 (en) * | 2002-09-13 | 2008-05-29 | Metcon Medicin Ab | COMPOSITION AND METHOD FOR USE IN DARM CLEANING PROCEDURES |
US7291324B2 (en) * | 2002-10-22 | 2007-11-06 | Braintree Laboratories Inc. | Method of bowel cleansing |
US6996500B2 (en) * | 2002-10-30 | 2006-02-07 | Hewlett-Packard Development Company, L.P. | Method for communicating diagnostic data |
US7049319B2 (en) * | 2003-09-23 | 2006-05-23 | Semaan Abboud | Colon cleansing composition and method |
CA2558219C (en) * | 2004-03-10 | 2014-04-08 | Taisho Pharmaceutical Co., Ltd. | Poorly water-soluble drug-containing solid formulation |
PL1750702T3 (en) | 2004-06-04 | 2011-04-29 | Braintree Laboratories Inc | Method of bowel cleansing |
US20060247180A1 (en) * | 2005-04-29 | 2006-11-02 | Bergey James L | Purgative composition and uses thereof |
NZ562942A (en) * | 2005-05-06 | 2012-02-24 | Salix Pharmaceuticals Ltd | Polyethylene glycol colonic purgative composition |
US20070082061A1 (en) * | 2005-10-07 | 2007-04-12 | Nelson Ayala | Reduction of saltiness with sweeteners |
JP2009521994A (en) * | 2005-12-29 | 2009-06-11 | ブレーントリー ラボラトリーズ インコーポレーティッド | A kit containing an osmotic laxative and a stimulant laxative for preparing the colon for virtual colonoscopy |
WO2010005965A1 (en) * | 2008-07-08 | 2010-01-14 | Aronchick Craig A | Colonic purgative formulations and methods of using the same |
US8211417B1 (en) | 2009-10-31 | 2012-07-03 | Harry Snady | Method of bowel cleansing |
WO2012016287A2 (en) | 2010-08-04 | 2012-02-09 | Borody Thomas J | Compositions for fecal floral transplantation and methods for making and using them and devices for deuvering them |
JP5494678B2 (en) | 2011-02-17 | 2014-05-21 | 株式会社ニコン | Illumination optical system and projector apparatus |
EP3610881A1 (en) | 2011-03-09 | 2020-02-19 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
TWI535461B (en) | 2011-03-11 | 2016-06-01 | 諾金私人有限公司 | Colon cleansing solutions,compositions for preparing the solutions,kits comprising the compositions or solutions,and methods for preparing the solutions |
WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
JP6655391B2 (en) | 2012-09-11 | 2020-02-26 | ノージン ビーブイ | Composition comprising PEG and ascorbate |
ME03656B (en) | 2013-03-15 | 2020-07-20 | Braintree Laboratories Inc | Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof |
EP3137167A4 (en) | 2014-04-29 | 2017-12-20 | Colonaryconcepts LLC | Foods, systems, methods, and kits for providing electrolyte replacement |
WO2016140981A1 (en) | 2015-03-02 | 2016-09-09 | Colonaryconcepts Llc | Compounds and methods for peg metabolite and peg breakdown product assays |
EP3294307A4 (en) | 2015-05-14 | 2019-01-23 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
JP6856968B2 (en) | 2015-05-22 | 2021-04-14 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | Methods for treating autism spectrum disorders and related symptoms |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
AU2018250206A1 (en) | 2017-04-05 | 2019-10-31 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (PD) and related disorders |
JP2020521760A (en) | 2017-05-26 | 2020-07-27 | クレストヴォ・ホールディングス・エルエルシー | Lyophilized compositions containing fecal microbial-based therapeutic agents and methods of making and using same |
US10143656B1 (en) | 2017-08-04 | 2018-12-04 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
CA3072032A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
WO2020069280A1 (en) | 2018-09-27 | 2020-04-02 | Crestovo Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232698A (en) * | 1992-06-12 | 1993-08-03 | The Proctor & Gamble Company | Psyllium drink mix compositions |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3088870A (en) * | 1958-11-25 | 1963-05-07 | Mcdermott Charles Byron | Low volume contact laxative enema compositions |
US3676553A (en) * | 1969-12-15 | 1972-07-11 | Cybersol | Therapeutic composition |
US3821368A (en) * | 1971-06-01 | 1974-06-28 | Cybersal Inc | Therapeutic composition |
US4104370A (en) * | 1974-07-10 | 1978-08-01 | Smith Kline & French Laboratories Limited | Method of treating magnesium/potassium depletion |
FR2401130A1 (en) * | 1977-08-23 | 1979-03-23 | Nativelle Sa Ets | Pure neutral potassium tartrate prepn. - from tartaric acid and potassium hydroxide soln. with alcohol addn. |
FR2471186A1 (en) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | NEW COLIC DELITESCENCE TABLETS AND THEIR PREPARATION PROCESS |
US4665100A (en) * | 1981-03-13 | 1987-05-12 | Eli Lilly And Company | Process for formulating a synthetic drug for use in animal feed, and resulting formulation |
US4452779A (en) * | 1982-02-03 | 1984-06-05 | Cockerill Vernon | Composition and method of treating lactating mammals |
US4476121A (en) * | 1983-03-01 | 1984-10-09 | Moss David W | Bowel evacuant and method of treating constipation |
US4725427A (en) * | 1984-03-13 | 1988-02-16 | Albion International, Inc. | Effervescent vitamin-mineral granule preparation |
US4812311A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
US4842871A (en) * | 1985-08-01 | 1989-06-27 | Pioneer Hi-Bred International, Inc. | Method and inoculant for preserving agricultural products for animal feed |
NO168563C (en) * | 1987-09-28 | 1992-03-11 | Collett Marwell Hauge As | USE OF AN ORGANOLEPTIC ACCEPTABLE MIXTURE OF MAGNESIUM SALTS AS MINERAL ADDITIVES |
US4904474A (en) * | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
AU3367589A (en) * | 1988-04-05 | 1989-11-03 | Dale Driver | Dietary mineral sulfur supplement |
GB8812490D0 (en) * | 1988-05-26 | 1988-06-29 | Agricultural & Food Res | Delayed release formulations |
IT1229568B (en) * | 1989-04-17 | 1991-09-04 | Giuliani Spa | PHARMACEUTICAL COMPOSITION FOR ORAL USE SUITABLE FOR USE IN GASTRO-INTESTINAL WASHING, IN PARTICULAR FOR DIAGNOSTIC USE, OR AS A CATHARTIC LAXATIVE. |
EP0484106A1 (en) * | 1990-11-01 | 1992-05-06 | Merck & Co. Inc. | Controlled release formulations |
JPH0515319A (en) * | 1990-12-14 | 1993-01-26 | Sunstar Inc | Method for dispersing sparingly water-soluble salts and drinking composition containing the same dispersed therein |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
AUPN634595A0 (en) * | 1995-11-03 | 1995-11-30 | Borody, Thomas Julius | Improved method for colonic evacuation |
DK0858326T3 (en) * | 1996-05-08 | 2003-07-07 | Craig A Aronchick | Non-aqueous colon laxatives |
US6162464A (en) * | 1997-03-31 | 2000-12-19 | Inkine Pharmaceutical, Inc. | Non-aqueous colonic purgative formulations |
-
1997
- 1997-03-31 US US08/829,080 patent/US6162464A/en not_active Expired - Lifetime
-
1998
- 1998-03-30 KR KR1019980709839A patent/KR20000016266A/en not_active Application Discontinuation
- 1998-03-30 NZ NZ332998A patent/NZ332998A/en not_active IP Right Cessation
- 1998-03-30 AU AU65913/98A patent/AU6591398A/en not_active Abandoned
- 1998-03-30 EP EP98912121A patent/EP0934071A4/en not_active Withdrawn
- 1998-03-30 JP JP54189598A patent/JP3706147B2/en not_active Expired - Lifetime
- 1998-03-30 EA EA199801086A patent/EA001443B1/en not_active IP Right Cessation
- 1998-03-30 CN CN98800569A patent/CN1225588A/en active Pending
- 1998-03-30 WO PCT/US1998/006224 patent/WO1998043654A1/en not_active Application Discontinuation
- 1998-03-30 CA CA002256896A patent/CA2256896C/en not_active Expired - Lifetime
-
2003
- 2003-08-21 JP JP2003297910A patent/JP4647893B2/en not_active Expired - Lifetime
-
2010
- 2010-11-17 JP JP2010257326A patent/JP2011032291A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232698A (en) * | 1992-06-12 | 1993-08-03 | The Proctor & Gamble Company | Psyllium drink mix compositions |
Non-Patent Citations (2)
Title |
---|
"GASTROINTESTINAL DISORDERS", PHARMACOTHERAPY. A PATHOPHYSIOLOGIC APPROACH, XX, XX, 1 January 1989 (1989-01-01), XX, pages 476 - 478, XP002912686 * |
FINGL E: "LAXATIVES AND ATHARTICS", PHARMACOLOGICAL BASIS OF THERAPEUTICS, XX, XX, 1 January 1980 (1980-01-01), XX, pages 1002 - 1005, XP002912685 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8361452B2 (en) * | 2002-07-15 | 2013-01-29 | Halow George M | Bowel cleansing composition |
US7658914B2 (en) | 2002-10-25 | 2010-02-09 | Norgine Bv | Colon cleansing compositions |
US8507009B2 (en) | 2003-11-19 | 2013-08-13 | Salix Pharmaceuticals, Inc. | Colonic purgative composition with soluble binding agent |
US7867521B2 (en) | 2004-09-03 | 2011-01-11 | C.B. Fleet Company, Incorporated | Aspartame and citrate flavored phosphate salt laxative |
US7985429B2 (en) | 2006-03-03 | 2011-07-26 | C. B. Fleet Company, Inc. | Flavored colonic cleansing system |
US8425944B2 (en) | 2006-03-03 | 2013-04-23 | C. B. Fleet Company, Inc. | Flavored colonic cleansing system |
DE102006017672B4 (en) * | 2006-04-12 | 2008-07-03 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Composition for use as a laxative |
DE102006017672A1 (en) * | 2006-04-12 | 2007-10-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Composition for use as a laxative |
US7998510B2 (en) | 2006-08-17 | 2011-08-16 | C. B. Fleet Company, Inc. | Low dose colonic cleansing system |
US8263136B2 (en) | 2006-08-17 | 2012-09-11 | C.B. Fleet Company Inc. | Low dose colonic cleansing system |
WO2008141368A1 (en) * | 2007-05-17 | 2008-11-27 | David Lubowski | Combination laxative compositions comprising a colonic stimulant and a bulking laxative |
US9468686B2 (en) | 2009-07-30 | 2016-10-18 | Norgine Bv | Solutions comprising polyethylene glycol and electrolytes |
US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
AU2012327212B2 (en) * | 2011-10-27 | 2016-05-12 | Rite-Prep Pty Ltd | Electrolyte purgatives |
WO2013059881A1 (en) * | 2011-10-27 | 2013-05-02 | Borody Thomas J | Electrolyte purgatives |
JP2018008997A (en) * | 2011-10-27 | 2018-01-18 | サリックス ファーマシューティカルズ,インコーポレイテッド | Electrolyte purgative |
US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
CN111024691A (en) * | 2019-12-26 | 2020-04-17 | 上海瘦斯网络科技有限公司 | Granules for absorbing animal urine and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
NZ332998A (en) | 2000-05-26 |
EA001443B1 (en) | 2001-04-23 |
JP3706147B2 (en) | 2005-10-12 |
JP4647893B2 (en) | 2011-03-09 |
KR20000016266A (en) | 2000-03-25 |
EP0934071A4 (en) | 2000-07-12 |
CA2256896C (en) | 2002-11-19 |
US6162464A (en) | 2000-12-19 |
AU6591398A (en) | 1998-10-22 |
JP2000500160A (en) | 2000-01-11 |
EA199801086A1 (en) | 1999-06-24 |
JP2011032291A (en) | 2011-02-17 |
JP2004043489A (en) | 2004-02-12 |
CA2256896A1 (en) | 1998-10-08 |
CN1225588A (en) | 1999-08-11 |
EP0934071A1 (en) | 1999-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6162464A (en) | Non-aqueous colonic purgative formulations | |
US5616346A (en) | Non-aqueous colonic purgative formulations | |
US6946149B2 (en) | Salt solution for colon cleansing | |
CA2189418C (en) | Method of colonic evacuation | |
US20070298008A1 (en) | Method of bowel cleansing | |
JP3047143B2 (en) | Composition for intestinal lavage and intestinal lavage | |
US20040170698A1 (en) | Bowel cleansing composition | |
US8129430B2 (en) | Method of reducing phosphate nephropathy in a mammal | |
EP1750702B1 (en) | Method of bowel cleansing | |
DE102006001199A1 (en) | Powder, useful e.g. to prepare drinking solution or finished solution, and in colon hydrotherapy, comprises polyethylene glycol, sodium hydrogen carbonate, sodium chloride and potassium chloride | |
JP2721929B2 (en) | Intestinal cleansing composition | |
MXPA98010032A (en) | Non-aqueous colonic purgative formulations | |
CN112870382A (en) | Arabinose and silicone oil type antifoaming agent combination for bowel preparation | |
WO2010005965A1 (en) | Colonic purgative formulations and methods of using the same | |
AU2002312652B2 (en) | Laxative preparation | |
Cittadini et al. | Cathartics and their combination | |
AU2002312652A1 (en) | Laxative preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98800569.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 332998 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2256896 Country of ref document: CA Ref document number: 2256896 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1998 541895 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980709839 Country of ref document: KR Ref document number: PA/a/1998/010032 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 65913/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998912121 Country of ref document: EP Ref document number: 199801086 Country of ref document: EA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998912121 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980709839 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998912121 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980709839 Country of ref document: KR |